Anacor Presents Data On Novel Mechanism Of Action For Its Topical Antifungal Treatment, AN2690

... AnacorPharmaceuticals, a privately held company, today announced that itsscientists presented AN2690's novel mechanism of action at the Society forInvestigative Dermatology Annual Meeting in Philadelphia. AN2690, the firstin a new class of antifungal agents, is being developed for onychomycosis,a fungal infection of the nail and nail bed that affects approximatelyseven to ten percent of the U... click link for more info. ...